Pharmaceuticals 11 February 2026 - 22 February 2026

GSK plc simplifies ViiV Healthcare ownership as Pfizer exits and Shionogi raises stake
···

GSK plc simplifies ViiV Healthcare ownership as Pfizer exits and Shionogi raises stake

GSK completed a reshaping of ViiV Healthcare’s ownership on April 1, with Shionogi raising its stake to 21.7% after Pfizer exited the HIV-focused venture. ViiV issued new shares to Shionogi for $2.125 billion and cancelled Pfizer’s holding. GSK retained a 78.3% majority and took a $250 million special dividend. The deal extinguished a put option liability tied to the old structure.
April 2, 2026
AbbVie stock (ABBV): FDA clears new Venclexta-Calquence CLL combo — what to watch Monday
···

AbbVie stock (ABBV): FDA clears new Venclexta-Calquence CLL combo — what to watch Monday

U.S. regulators approved a new first-line regimen for chronic lymphocytic leukemia combining AbbVie’s Venclexta and AstraZeneca’s Calquence, citing improved progression-free survival in the AMPLIFY study. AbbVie shares closed Friday up 0.21% at $224.81. Barclays initiated coverage with an overweight rating and a $275 price target. Investors await market reaction when trading resumes Monday.
February 22, 2026
Grail stock halves after UK cancer trial miss; FDA and Medicare stakes rise
···

Grail stock halves after UK cancer trial miss; FDA and Medicare stakes rise

Grail shares fell about 50% to $50.21 in after-hours trading after its Galleri cancer blood test missed the main goal in a major UK trial. The study failed to show a statistically significant drop in late-stage cancers. Grail said it will release fuller data later this spring and extend trial follow-up. Investors are watching for U.S. regulatory and Medicare decisions.
February 20, 2026
Recursion Pharmaceuticals stock slides premarket as Novo Holdings exits stake — what to watch for RXRX
···

Recursion Pharmaceuticals stock slides premarket as Novo Holdings exits stake — what to watch for RXRX

Recursion Pharmaceuticals shares fell about 12% to $3.05 in premarket trading after a regulatory filing showed Novo Holdings A/S no longer reported a stake as of December 31. Novo had previously held nearly 8 million shares. Recursion closed at $3.46 on Tuesday. Investors await the company’s next earnings report and pipeline update.
February 18, 2026
Healthcare stocks head into Presidents Day break on Moderna rebound, Wegovy copycat fight
···

Healthcare stocks head into Presidents Day break on Moderna rebound, Wegovy copycat fight

The S&P 500 Health Care index rose 1.01% to 1,835.92 on Friday, with Dexcom up 7.6% and Moderna up 5.3% after earnings. Moderna warned of regulatory uncertainty after the FDA refused to review its flu shot. Disc Medicine shares fell 21% after the FDA declined to approve its rare-disease drug. U.S. markets close Monday for Presidents Day; Medtronic reports Tuesday.
February 14, 2026
AbbVie stock price climbs again after Botox lawsuit; what ABBV traders watch next
···

AbbVie stock price climbs again after Botox lawsuit; what ABBV traders watch next

AbbVie shares rose 1.8% to $231.50 in after-hours trading Friday following updates on its drug pipeline and ongoing litigation over Botox’s inclusion in Medicare price negotiations. Botox made up just over 10% of AbbVie’s $61.16 billion revenue last year. Investors are watching for mid-stage trial results in hidradenitis suppurativa and inflammatory bowel disease later this year. The next court update in the Botox case is expected Monday.
February 14, 2026
Merck (MRK) stock swings, ends flat after FDA clears Keytruda regimen in ovarian cancer
···

Merck (MRK) stock swings, ends flat after FDA clears Keytruda regimen in ovarian cancer

Merck shares closed down 0.03% at $119.28 after the FDA approved a Keytruda-based regimen for certain platinum-resistant ovarian cancer patients. The stock had reached $121.62 earlier in the session. Merck also announced new bladder and kidney cancer data to be presented at ASCO GU later this month. Chief Marketing Officer Chirfi Guindo sold 10,000 shares at an average price of $121.46.
February 12, 2026
Viking Therapeutics stock (VKTX) slips premarket as Phase 3 obesity pill timeline comes into focus
···

Viking Therapeutics stock (VKTX) slips premarket as Phase 3 obesity pill timeline comes into focus

Viking Therapeutics shares fell 0.7% to $28.55 in premarket trading Thursday after outlining plans to advance its oral obesity drug VK2735 into Phase 3 trials in the third quarter of 2026. The company completed enrollment for a Phase 3 injectable VK2735 study and reported a fourth-quarter net loss of $157.7 million, ending 2025 with $706 million in cash and equivalents.
February 12, 2026
1 2